search
Back to results

Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars

Primary Purpose

Colorectal Cancer, Recurrence, Local Neoplasm

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
WLE followed by NBI or NBI followed by WLE (crossover design)
Sponsored by
Portuguese Oncology Institute, Coimbra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Cancer focused on measuring recurrence, endoscopic mucosal resection, colorectal lesions, advanced endoscopic imaging

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients undergoing the first follow-up surveillance colonoscopy after successful EMR of colorectal lesion.

Exclusion Criteria:

  • informed consent not provided,
  • inflammatory bowel disease, inadequate bowel preparation (Boston Bowel Preparation Scale total score < 6 or < 2 in a segment),
  • EMR scar not identified during colonoscopy,
  • tissue acquisition unfeasibly.

Sites / Locations

  • Portuguese Oncology Institute - Coimbra

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A: WLE followed by NBI

Group B: NBI followed by WLE

Arm Description

EMR scar is interrogated using WLE followed by NBI

EMR scar is interrogated using NBI followed by WLE

Outcomes

Primary Outcome Measures

Diagnostic performance of WLE and NBI for each group
Sensitivity, specificity, negative predictive value, positive predictive value and accuracy of NBI and WLE for each group calculated using 2x2 contingency tables
Recurrent adenoma - WLE
WLE recurrent adenoma identification for each group
Recurrent adenoma - NBI
NBI recurrent adenoma identification for each group
Recurrent adenoma - histology
Adenoma recurrence confirmed by histology

Secondary Outcome Measures

Lesion characterization at the baseline colonoscopy
Lesion size and location, Paris classification, NICE classification, number of pieces, use of adjunctive ablative techniques and those identification and histology. Data collected by endoscopic reports consultation
Scar characterization at the first surveillance colonoscopy
Scar size, presence or absence of recurrence, in case of recurrence: number of sites, location (edge of the scar, within the scar or both), morphology of recurrence, NICE classification (for NBI evaluation)

Full Information

First Posted
January 20, 2020
Last Updated
October 3, 2022
Sponsor
Portuguese Oncology Institute, Coimbra
search

1. Study Identification

Unique Protocol Identification Number
NCT04239365
Brief Title
Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars
Official Title
Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars: a Multicentre Randomized Single-blinded Crossover Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
January 31, 2020 (Actual)
Primary Completion Date
May 31, 2022 (Actual)
Study Completion Date
May 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Portuguese Oncology Institute, Coimbra

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Nowadays endoscopic mucosal resection (EMR) is the gold standard for the removal of large laterally spreading and sessile colorectal lesions ≥ 20 mm. However, recurrence rate after successful EMR (defined by the absence of neoplastic tissue at the completion of the procedure after careful inspection of the post-EMR mucosal defect and margin) is about 15-20%. Consequently, current guidelines recommend a surveillance colonoscopy between 4 and 6 months after resection for detection of residual or recurrent polyp. There are few studies that have examined the accuracy of advanced endoscopic imaging for the prediction of histological recurrence but none of these imaging modalities have been validated for surveillance after EMR. Therefore, current guidelines strongly recommend systematic biopsy of EMR scar. The main aim of this study is to assess the incremental benefit of narrow band imaging (NBI) and white light endoscopy (WLE) randomizing the initial technique for the endoscopic detection of post-EMR recurrence and to asses if this advanced imaging method achieve sufficient diagnostic accuracy to exclude recurrence without the need for biopsy.
Detailed Description
a. Study type: multicenter randomized crossover trial: i. prospective inclusion of consecutive patients undergoing first follow-up surveillance colonoscopy after successful EMR of colorectal lesion; ii. crossover randomization by computer generated tables; iii. allocation concealment by sealed, opaque envelopes; iv. pathologist-blinded - pathologists are blinded to the study protocol and samples are received as 'EMR scar for assessment' . b. Selection patient method: inclusion by invitation of patients undergoing the first follow-up surveillance colonoscopy after successful EMR of colorectal lesion. c. Sample size: 210 (two groups of 105 patients). To improve accuracy from 85% (value obtained by a study that did not show significant differences in the accuracy of NBI followed by WLE vs. WLE followed by NBI) to 95% and assuming a normal distribution and a power of 80% (α=0.05), the calculated sample size of each of the 2 groups was 96; allowing for a 10% dropout rate, the sample size is 105 per group (210 patients overall). d. Procedures and data collection methods: i. Each procedure is performed by the same endoscopist. ii. All patients receive split dose bowel preparation. iii. All colonoscopies are performed using high definition colonoscopes with NBI ( EVIS EXERA III CV 185 and CV 190; Olympus Inc., Tokyo, Japan). iv. Colon inspection is done with WLE during withdrawal. v. At the proximity of the scar WLE and NBI were used randomly one after the other (WLE>NBI or NBI>WLE). If NBI is the first technique used, it is switched prior to scar detection, avoiding, as far as possible, a glance with WLE. The edges of the scar are interrogated followed by the centre of the scar and finding are recorded. vi. After both evaluations, if there is no suspicion of recurrence, the site is sampled by at least 2 biopsies of the scar edge. If there is any suspicion of recurrence, tissue sample is obtained and then treated by endoscopic resection using standard methods. At least 2 biopsies specimens from normal appearing scar are also obtained. e. Analysed variables: i. patient characteristics; ii. data from baseline colonoscopy; iii. data from first surveillance colonoscopy (see outcome measures). f. Statistical analysis: i. Performed using statistical software IBM SPSS Statistics, Version 25.0. Armonk, NY: IBM Corp. ii. Continuous variables are reported as mean and standard deviation or median and interquartile range, if they have normal or not normal distribution, respectively; categorical variables as absolute and relative frequency. iii. Continuous variables are compared between two groups using Student's T test if they have a normal distribution and homogeneity of variance or Mann-Whitney U if these conditions are not met. Categorical variables are compared using Pearson's X2 test or Fisher test. iv. Sensitivity, specificity, negative and positive predictive values and accuracy are calculated using 2x2 contingency tables. v. All hypotheses are two-tailed and a P-value<0.05 is considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Recurrence, Local Neoplasm
Keywords
recurrence, endoscopic mucosal resection, colorectal lesions, advanced endoscopic imaging

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Care Provider
Allocation
Randomized
Enrollment
210 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: WLE followed by NBI
Arm Type
Experimental
Arm Description
EMR scar is interrogated using WLE followed by NBI
Arm Title
Group B: NBI followed by WLE
Arm Type
Active Comparator
Arm Description
EMR scar is interrogated using NBI followed by WLE
Intervention Type
Diagnostic Test
Intervention Name(s)
WLE followed by NBI or NBI followed by WLE (crossover design)
Other Intervention Name(s)
WLE followed by NBI or NBI followed by WLE
Intervention Description
EMR scar is inspected using WLE followed by NBI or vice versa
Primary Outcome Measure Information:
Title
Diagnostic performance of WLE and NBI for each group
Description
Sensitivity, specificity, negative predictive value, positive predictive value and accuracy of NBI and WLE for each group calculated using 2x2 contingency tables
Time Frame
1 day (at the time of data analysis)
Title
Recurrent adenoma - WLE
Description
WLE recurrent adenoma identification for each group
Time Frame
1 day (during colonoscopy)
Title
Recurrent adenoma - NBI
Description
NBI recurrent adenoma identification for each group
Time Frame
1 day (during colonoscopy)
Title
Recurrent adenoma - histology
Description
Adenoma recurrence confirmed by histology
Time Frame
1 day (within 30 days from colonoscopy)
Secondary Outcome Measure Information:
Title
Lesion characterization at the baseline colonoscopy
Description
Lesion size and location, Paris classification, NICE classification, number of pieces, use of adjunctive ablative techniques and those identification and histology. Data collected by endoscopic reports consultation
Time Frame
1 day (at the time of patient inclusion)
Title
Scar characterization at the first surveillance colonoscopy
Description
Scar size, presence or absence of recurrence, in case of recurrence: number of sites, location (edge of the scar, within the scar or both), morphology of recurrence, NICE classification (for NBI evaluation)
Time Frame
1 day (immediately after first surveillance colonoscopy)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients undergoing the first follow-up surveillance colonoscopy after successful EMR of colorectal lesion. Exclusion Criteria: informed consent not provided, inflammatory bowel disease, inadequate bowel preparation (Boston Bowel Preparation Scale total score < 6 or < 2 in a segment), EMR scar not identified during colonoscopy, tissue acquisition unfeasibly.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel Areia, PhD
Organizational Affiliation
Gastroenterology Department
Official's Role
Study Director
Facility Information:
Facility Name
Portuguese Oncology Institute - Coimbra
City
Coimbra
ZIP/Postal Code
3001 - 651
Country
Portugal

12. IPD Sharing Statement

Citations:
PubMed Identifier
22987217
Citation
Rembacken B, Hassan C, Riemann JF, Chilton A, Rutter M, Dumonceau JM, Omar M, Ponchon T. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy. 2012 Oct;44(10):957-68. doi: 10.1055/s-0032-1325686. Epub 2012 Sep 17. No abstract available.
Results Reference
background
PubMed Identifier
27908600
Citation
Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, Williams SJ, Zanati S, Byth K, Bourke MJ. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool. Gastrointest Endosc. 2017 Mar;85(3):647-656.e6. doi: 10.1016/j.gie.2016.11.027. Epub 2016 Nov 28.
Results Reference
background
PubMed Identifier
24030244
Citation
Hassan C, Quintero E, Dumonceau JM, Regula J, Brandao C, Chaussade S, Dekker E, Dinis-Ribeiro M, Ferlitsch M, Gimeno-Garcia A, Hazewinkel Y, Jover R, Kalager M, Loberg M, Pox C, Rembacken B, Lieberman D; European Society of Gastrointestinal Endoscopy. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2013 Oct;45(10):842-51. doi: 10.1055/s-0033-1344548. Epub 2013 Sep 12.
Results Reference
background
PubMed Identifier
28212588
Citation
Ferlitsch M, Moss A, Hassan C, Bhandari P, Dumonceau JM, Paspatis G, Jover R, Langner C, Bronzwaer M, Nalankilli K, Fockens P, Hazzan R, Gralnek IM, Gschwantler M, Waldmann E, Jeschek P, Penz D, Heresbach D, Moons L, Lemmers A, Paraskeva K, Pohl J, Ponchon T, Regula J, Repici A, Rutter MD, Burgess NG, Bourke MJ. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017 Mar;49(3):270-297. doi: 10.1055/s-0043-102569. Epub 2017 Feb 17.
Results Reference
background
PubMed Identifier
27343411
Citation
Desomer L, Tutticci N, Tate DJ, Williams SJ, McLeod D, Bourke MJ. A standardized imaging protocol is accurate in detecting recurrence after EMR. Gastrointest Endosc. 2017 Mar;85(3):518-526. doi: 10.1016/j.gie.2016.06.031. Epub 2016 Jun 22.
Results Reference
background
PubMed Identifier
30635409
Citation
Kandel P, Brand EC, Pelt J, Ball CT, Chen WC, Bouras EP, Gomez V, Raimondo M, Woodward TA, Wallace MB; EMR SCAR Group. Endoscopic scar assessment after colorectal endoscopic mucosal resection scars: when is biopsy necessary (EMR Scar Assessment Project for Endoscope (ESCAPE) trial). Gut. 2019 Sep;68(9):1633-1641. doi: 10.1136/gutjnl-2018-316574. Epub 2019 Jan 11.
Results Reference
background
PubMed Identifier
30568394
Citation
Riu Pons F, Andreu M, Gimeno Beltran J, Alvarez-Gonzalez MA, Seoane Urgorri A, Dedeu JM, Barranco Priego L, Bessa X. Narrow band imaging and white light endoscopy in the characterization of a polypectomy scar: A single-blind observational study. World J Gastroenterol. 2018 Dec 7;24(45):5179-5188. doi: 10.3748/wjg.v24.i45.5179.
Results Reference
background
PubMed Identifier
23910062
Citation
Hayashi N, Tanaka S, Hewett DG, Kaltenbach TR, Sano Y, Ponchon T, Saunders BP, Rex DK, Soetikno RM. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. Gastrointest Endosc. 2013 Oct;78(4):625-32. doi: 10.1016/j.gie.2013.04.185. Epub 2013 Jul 30.
Results Reference
background
PubMed Identifier
14652541
Citation
The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43. doi: 10.1016/s0016-5107(03)02159-x. No abstract available.
Results Reference
background

Learn more about this trial

Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars

We'll reach out to this number within 24 hrs